FDA PMA FDA Class 3 Approved 🇺🇸 United States

Somatic Gene Mutation Detection System

PMA: P140023 · Supplement: S004 · Decision Sep 24, 2016
Classifications
1
FEI Numbers
11
Registration Numbers
11

Basic Information

Device Name
Somatic Gene Mutation Detection System
Trade Name
COBAS KRAS MUTATION TEST
PMA Number
P140023
Supplement Number
S004
Device Class
FDA Class 3
Product Code
OWD
Generic Name
Somatic gene mutation detection system
Medical Specialty
Unknown
Advisory Committee
Pathology
Decision
Approved
Decision Code
APPR
Decision Date
September 24, 2016
Date Received
February 29, 2016
Supplement Type
Normal 180 Day Track
Supplement Reason
Labeling Change - Indications/instructions/shelf life/tradename
Expedited Review
N

Advisory Committee Statement

The cobas® KRAS Mutation Test, for use with the cobas® 4800 System, is a real-time PCR test for the detection of mutations in codons 12, 13 and 61 of the KRAS gene in DNA derived from formalin-fixed paraffin-embedded human colorectal cancer (CRC) tumor tissue. The test is intended to be used as an aid in the identification of CRC patients who should not be treated with Erbitux® (cetuximab) or with Vectibix® (panitumumab) when KRAS Codon 12 or 13 mutation is detected. Safety and efficacy of Erbitux® (cetuximab) or Vectibix® (panitumumab) have not been established in patients whose tumors have Codon 61 mutation. Specimens are processed using the cobas® DNA Sample Preparation Kit for manual sample preparation and the cobas z 480 analyzer for automated amplification and detection.

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
OWD Somatic Gene Mutation Detection System